Literature DB >> 23466647

Cost-effective diagnostic checklists for meningitis in resource-limited settings.

Kara N Durski1, Karen M Kuntz, Kosuke Yasukawa, Beth A Virnig, David B Meya, David R Boulware.   

Abstract

BACKGROUND: Checklists can standardize patient care, reduce errors, and improve health outcomes. For meningitis in resource-limited settings, with high patient loads and limited financial resources, central nervous system diagnostic algorithms may be useful to guide diagnosis and treatment. However, the cost effectiveness of such algorithms is unknown.
METHODS: We used decision analysis methodology to evaluate the costs, diagnostic yield, and cost effectiveness of diagnostic strategies for adults with suspected meningitis in resource-limited settings with moderate/high HIV prevalence. We considered 3 strategies: (1) comprehensive "shotgun" approach of utilizing all routine tests; (2) "stepwise" strategy with tests performed in a specific order with additional tuberculosis (TB) diagnostics; (3) "minimalist" strategy of sequential ordering of high-yield tests only. Each strategy resulted in 1 of 4 meningitis diagnoses: bacterial (4%), cryptococcal (59%), TB (8%), or other (aseptic) meningitis (29%). In model development, we utilized prevalence data from 2 Ugandan sites and published data on test performance. We validated the strategies with data from Malawi, South Africa, and Zimbabwe.
RESULTS: The current comprehensive testing strategy resulted in 93.3% correct meningitis diagnoses costing $32.00 per patient. A stepwise strategy had 93.8% correct diagnoses costing an average of $9.72 per patient, and a minimalist strategy had 91.1% correct diagnoses costing an average of $6.17 per patient. The incremental cost-effectiveness ratio was $133 per additional correct diagnosis for the stepwise over minimalist strategy.
CONCLUSIONS: Through strategically choosing the order and type of testing coupled with disease prevalence rates, algorithms can deliver more care more efficiently. The algorithms presented herein are generalizable to East Africa and Southern Africa.

Entities:  

Mesh:

Year:  2013        PMID: 23466647      PMCID: PMC3683123          DOI: 10.1097/QAI.0b013e31828e1e56

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  35 in total

1.  Impact of HIV infection on meningitis in Harare, Zimbabwe: a prospective study of 406 predominantly adult patients.

Authors:  J G Hakim; I T Gangaidzo; R S Heyderman; J Mielke; E Mushangi; A Taziwa; V J Robertson; P Musvaire; P R Mason
Journal:  AIDS       Date:  2000-07-07       Impact factor: 4.177

2.  Microscopic examination and broth culture of cerebrospinal fluid in diagnosis of meningitis.

Authors:  S A Dunbar; R A Eason; D M Musher; J E Clarridge
Journal:  J Clin Microbiol       Date:  1998-06       Impact factor: 5.948

3.  Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings.

Authors:  David B Meya; Yukari C Manabe; Barbara Castelnuovo; Bethany A Cook; Ali M Elbireer; Andrew Kambugu; Moses R Kamya; Paul R Bohjanen; David R Boulware
Journal:  Clin Infect Dis       Date:  2010-08-15       Impact factor: 9.079

4.  Comparison of two nucleic acid amplification assays, the Xpert MTB/RIF assay and the amplified Mycobacterium Tuberculosis Direct assay, for detection of Mycobacterium tuberculosis in respiratory and nonrespiratory specimens.

Authors:  Jeanette Teo; Roland Jureen; Donald Chiang; Douglas Chan; Raymond Lin
Journal:  J Clin Microbiol       Date:  2011-08-24       Impact factor: 5.948

5.  Lumbar puncture in pediatric bacterial meningitis: defining the time interval for recovery of cerebrospinal fluid pathogens after parenteral antibiotic pretreatment.

Authors:  J T Kanegaye; P Soliemanzadeh; J S Bradley
Journal:  Pediatrics       Date:  2001-11       Impact factor: 7.124

6.  Molecular analysis of Mycobacterium tuberculosis causing multidrug-resistant tuberculosis meningitis.

Authors:  M Caws; G E Thwaites; P M Duy; D Q Tho; N T Ngoc Lan; D V Hoa; T T Hong Chau; M N Thu Huyen; P T Hoang Anh; N V V Chau; T N T Chinh; K Stepniewska; J Farrar
Journal:  Int J Tuberc Lung Dis       Date:  2007-02       Impact factor: 2.373

7.  Glycerol adjuvant therapy in adults with bacterial meningitis in a high HIV seroprevalence setting in Malawi: a double-blind, randomised controlled trial.

Authors:  Katherine Mb Ajdukiewicz; Katharine E Cartwright; Matthew Scarborough; James B Mwambene; Patrick Goodson; Malcolm E Molyneux; Eduard E Zijlstra; Neil French; Christopher Jm Whitty; David G Lalloo
Journal:  Lancet Infect Dis       Date:  2011-02-18       Impact factor: 25.071

Review 8.  Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS.

Authors:  Benjamin J Park; Kathleen A Wannemuehler; Barbara J Marston; Nelesh Govender; Peter G Pappas; Tom M Chiller
Journal:  AIDS       Date:  2009-02-20       Impact factor: 4.177

9.  Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.

Authors:  John R Perfect; William E Dismukes; Francoise Dromer; David L Goldman; John R Graybill; Richard J Hamill; Thomas S Harrison; Robert A Larsen; Olivier Lortholary; Minh-Hong Nguyen; Peter G Pappas; William G Powderly; Nina Singh; Jack D Sobel; Tania C Sorrell
Journal:  Clin Infect Dis       Date:  2010-02-01       Impact factor: 9.079

10.  A phase II randomized controlled trial adding oral flucytosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis.

Authors:  Arthur T Jackson; Jesse C Nussbaum; Jacob Phulusa; Dan Namarika; Maria Chikasema; Creto Kanyemba; Joseph N Jarvis; Shabbar Jaffar; Mina C Hosseinipour; Charles van der Horst; Thomas S Harrison
Journal:  AIDS       Date:  2012-07-17       Impact factor: 4.177

View more
  71 in total

1.  Evaluation of the Dynamiker Cryptococcal Antigen Lateral Flow Assay for the Diagnosis of HIV-Associated Cryptococcosis.

Authors:  Richard Kwizera; Denis Omali; Kiiza Tadeo; John Kasibante; Morris K Rutakingirwa; Enock Kagimu; Kenneth Ssebambulidde; Darlisha A Williams; Joshua Rhein; David Boulware; David B Meya
Journal:  J Clin Microbiol       Date:  2021-02-18       Impact factor: 5.948

2.  Predictors of neurocognitive outcomes on antiretroviral therapy after cryptococcal meningitis: a prospective cohort study.

Authors:  Renee Donahue Carlson; Melissa A Rolfes; Kate E Birkenkamp; Noeline Nakasujja; Radha Rajasingham; David B Meya; David R Boulware
Journal:  Metab Brain Dis       Date:  2014-01-09       Impact factor: 3.584

3.  Point-of-care diagnosis and prognostication of cryptococcal meningitis with the cryptococcal antigen lateral flow assay on cerebrospinal fluid.

Authors:  Taseera Kabanda; Mark J Siedner; Jeffrey D Klausner; Conrad Muzoora; David R Boulware
Journal:  Clin Infect Dis       Date:  2013-09-24       Impact factor: 9.079

4.  Delta-like 1 protein, vitamin D binding protein and fetuin for detection of Mycobacterium tuberculosis meningitis.

Authors:  Nathan C Bahr; Ryan Halupnick; Grace Linder; Reuben Kiggundu; Henry W Nabeta; Darlisha A Williams; Abdu K Musubire; Bozena M Morawski; Srinand Sreevatsan; David B Meya; Joshua Rhein; David R Boulware
Journal:  Biomark Med       Date:  2018-06-01       Impact factor: 2.851

Review 5.  Chronic Meningitis.

Authors:  Kiran T Thakur; Michael R Wilson
Journal:  Continuum (Minneap Minn)       Date:  2018-10

6.  Short-course amphotericin B in addition to sertraline and fluconazole for treatment of HIV-associated cryptococcal meningitis in rural Tanzania.

Authors:  Andrew Katende; Gladys Mbwanji; Diana Faini; Amina Nyuri; Aneth Vedastus Kalinjuma; Dorcas Mnzava; Katherine H Hullsiek; Joshua Rhein; Maja Weisser; David B Meya; David R Boulware; Emilio Letang
Journal:  Mycoses       Date:  2019-10-21       Impact factor: 4.377

7.  Diagnostic accuracy of Xpert MTB/RIF for tuberculous meningitis: systematic review and meta-analysis.

Authors:  Adrian V Hernandez; Laryssa de Laurentis; Isadora Souza; Marcelo Pessanha; Priyaleela Thota; Yuani M Roman; Joshuan Barboza-Meca; David R Boulware; Jose E Vidal
Journal:  Trop Med Int Health       Date:  2020-11-30       Impact factor: 2.622

8.  Altered mental status is an indicator of mortality and associated with both infectious and non-communicable disease in Lilongwe, Malawi.

Authors:  Bryna Harrington; Charles Kyriakos Vorkas; Cecilia Kanyama; Jonathan Ngoma; Irving Hoffman; Mina C Hosseinipour
Journal:  Trop Doct       Date:  2015-03-29       Impact factor: 0.731

Review 9.  The immunopathogenesis of cryptococcal immune reconstitution inflammatory syndrome: understanding a conundrum.

Authors:  David B Meya; Yukari C Manabe; David R Boulware; Edward N Janoff
Journal:  Curr Opin Infect Dis       Date:  2016-02       Impact factor: 4.915

10.  Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis.

Authors:  David R Boulware; David B Meya; Conrad Muzoora; Melissa A Rolfes; Katherine Huppler Hullsiek; Abdu Musubire; Kabanda Taseera; Henry W Nabeta; Charlotte Schutz; Darlisha A Williams; Radha Rajasingham; Joshua Rhein; Friedrich Thienemann; Melanie W Lo; Kirsten Nielsen; Tracy L Bergemann; Andrew Kambugu; Yukari C Manabe; Edward N Janoff; Paul R Bohjanen; Graeme Meintjes
Journal:  N Engl J Med       Date:  2014-06-26       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.